Etuvetidigene Autotemcel RDEB Gene Therapy — PatSnap Eureka
Etuvetidigene Autotemcel: Ex Vivo Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
COL7A1-corrected autologous keratinocyte grafts, Krystal Biotech's HSV-1 platform IP, VIITAL Phase 3 data, and commercialization signals — all mapped through PatSnap Eureka patent and literature intelligence.
COL7A1 Mutations Disrupt Anchoring Fibrils at the Dermal-Epidermal Junction
Recessive dystrophic epidermolysis bullosa (RDEB) is a life-threatening genodermatosis caused by loss-of-function mutations in COL7A1, the gene encoding type VII collagen. Type VII collagen is the principal structural component of anchoring fibrils at the dermal-epidermal junction (DEJ) — the molecular interface that prevents skin layers from separating under mechanical stress. When COL7A1 is mutated, anchoring fibril formation fails, producing the severe blistering, chronic wound burden, and elevated squamous cell carcinoma risk characteristic of RDEB. A comprehensive 2024 review by Uitto J et al. maps the full COL7A1 mutation landscape and validates gene-corrective intervention as the primary therapeutic strategy.
Retrieved patent filings from PatSnap's IP analytics platform show that Krystal Biotech's patent portfolio consistently anchors intervention at anchoring fibril restoration via COL7A1 delivery — present in 12 of 25 retrieved items. The patent Compositions and Methods for Treating a Disease or Condition of the Skin (Krystal Biotech, 2024) specifically elaborates methods for anchoring fibril reformation as the mechanistic output of COL7A1 restoration.
Beyond RDEB, the same HSV-1 platform addresses LAMB3 (encoding laminin-332) for junctional EB (JEB), and SPINK5 (encoding serine protease inhibitor LEKTI) for Netherton syndrome — demonstrating a multi-target, multi-indication IP strategy built on a single vector backbone. The PatSnap life sciences solutions team tracks this platform expansion across disease areas.
Ex Vivo and In Vivo HSV-1 Gene Therapy for RDEB
Krystal Biotech's HSV-1 platform supports two clinically validated delivery routes for COL7A1 restoration in RDEB, with distinct manufacturing, durability, and regulatory profiles.
Etuvetidigene Autotemcel (EB-101)
Patient keratinocytes are harvested, transduced ex vivo with an HSV-1 vector encoding wild-type COL7A1, expanded under GMP conditions, and transplanted back as corrected autologous skin grafts. Phase 1/2 clinical data report durable wound healing. Long-term follow-up data (Siprashvili Z et al., 2023) confirm sustained type VII collagen restoration and stable keratinocyte engraftment over 2+ years. The VIITAL Phase 3 trial documents wound surface area reduction and type VII collagen restoration confirmed by immunofluorescence.
Stable engraftment >2 years · VIITAL Phase 3Beremagene Geperpavec (B-VEC / Vyjuvek)
Topical in vivo delivery of the same HSV-1-COL7A1 vector as a gel applied directly to wounds. In a Phase 3 randomized controlled trial (Marinkovich MP, Genovese G et al., 2023), 67% of B-VEC-treated wounds achieved complete wound closure versus 22% in placebo-treated wounds at 6 months. Received FDA Breakthrough Therapy Designation and Orphan Drug Designation. Commercialization analysis references FDA approval in May 2023 for RDEB and active commercial launch.
67% complete closure vs 22% placebo · FDA approvedRepeat-Dose HSV-1 Administration
A distinct IP cluster addresses the challenge of repeat vector administration. The patent Methods for Repeat Administration of Gene Therapy Vectors (Krystal Biotech, 2021) claims methods for overcoming immune barriers to redosing via subcutaneous and topical routes. This is analytically relevant to both ex vivo re-grafting and topical delivery strategies where repeat treatment may be required for chronic wound management in RDEB patients.
Immune barrier management · subcutaneous + topical routesPlatform Extension to Other Genodermatoses
Retrieved patent filings demonstrate HSV-1 platform extension beyond EB. Gene Therapy for Skin Diseases (Krystal Biotech, 2024) claims broad multi-transgene delivery for RDEB, Netherton syndrome (SPINK5/LEKTI), and other rare skin diseases. Academic literature (Has C, Kiritsi D et al., 2023) identifies the Krystal Biotech HSV-1 platform as a case study for multi-indication strategy extending to TGM1-deficient lamellar ichthyosis and wound healing applications.
RDEB · JEB · Netherton · Lamellar ichthyosisKey Quantitative Signals from Patent and Literature Analysis
Data derived from 10 patent filings and 15 literature sources retrieved across targeted PatSnap Eureka searches covering etuvetidigene autotemcel, B-VEC, and the Krystal Biotech HSV-1 platform.
Complete Wound Closure Rate: B-VEC vs Placebo at 6 Months
Phase 3 RCT data showing 67% complete wound closure for beremagene geperpavec versus 22% for placebo in RDEB patients treated for 6 months.
Krystal Biotech HSV-1 Platform: Target Coverage Across Retrieved Items
COL7A1 (RDEB) dominates patent and literature coverage at 48% of 25 retrieved items, with platform extension signals for JEB, Netherton, and other genodermatoses.
Krystal Biotech HSV-1 Platform: Patent Filing Activity 2021–2024
Retrieved Krystal Biotech US patent publications show accelerating filing activity from 2021 through 2024, with peak output in 2023 reflecting RDEB and platform expansion filings.
HSV-1 Vector Technical Advantages for Skin Gene Therapy
Key technical properties of the HSV-1 vector platform that underpin Krystal Biotech's competitive position in skin gene therapy versus integrating retroviral and lentiviral systems.
Krystal Biotech's Multi-Layer HSV-1 IP Architecture
Retrieved patent filings reveal a layered IP strategy spanning vector compositions, delivery methods, manufacturing, and multi-indication platform claims.
Composition Claims: HSV-1-COL7A1 Vector
The core IP layer covers recombinant HSV-1 vector compositions encoding COL7A1 for RDEB treatment. Multiple patents (2023, 2024) claim ex vivo and in vivo delivery methods, keratinocyte and fibroblast transduction, and restoration of type VII collagen expression — protecting both the vector construct and the therapeutic mechanism.
Method Claims: Repeat Administration
A 2021 patent specifically claims methods for repeat dosing of HSV-1-based gene therapy vectors in skin applications including RDEB, addressing immune barriers to re-administration. This is strategically important for chronic wound management and distinguishes the HSV-1 platform from single-dose ex vivo approaches requiring repeat grafting procedures.
RDEB Gene Therapy: Clinical Milestones and Market Access Signals
Key data points from retrieved clinical trial publications and commercialization analyses covering both EB-101 (etuvetidigene autotemcel) and B-VEC (Vyjuvek).
| Program | Modality | Stage (per retrieved data) | Key Clinical Signal | Regulatory / Commercial |
|---|---|---|---|---|
| Etuvetidigene autotemcel (EB-101) | Ex vivo autologous keratinocyte graft | Phase 3 Completed | Stable engraftment >2 years; wound surface area reduction; type VII collagen by IHC in VIITAL trial | BLA pathway; FDA Orphan Drug Designation referenced |
| Beremagene geperpavec (B-VEC / Vyjuvek) | Topical in vivo HSV-1-COL7A1 gel | FDA Approved | 67% complete wound closure vs 22% placebo at 6 months (Phase 3 RCT) | FDA approved May 2023; Breakthrough Therapy + Orphan Drug Designations; commercial launch active |
| HSV-1-LAMB3 (JEB program) | HSV-1 vector encoding LAMB3 | Preclinical / IP | Laminin-332 subunit restoration; DEJ repair in JEB patient-derived models | Patent filed 2023; platform extension signal |
| HSV-1-SPINK5 (Netherton program) | HSV-1 vector encoding SPINK5/LEKTI | Preclinical / IP | LEKTI serine protease inhibitor restoration in Netherton syndrome models | Patent filed 2022; multi-indication platform IP |
Track RDEB Gene Therapy Regulatory Milestones in Real Time
PatSnap Eureka monitors BLA submissions, approval signals, and competitor filings across the genodermatosis gene therapy landscape.
From Wound Closure to Quality of Life: Patient-Reported Evidence
Retrieved literature from the VIITAL trial cohort documents patient-reported outcome improvements beyond wound closure metrics. Pain NRS score reductions and itch NRS score reductions are reported following EB-101 treatment, with wound closure outcomes correlating with patient-perceived benefit (Eichenfield LF et al., 2023). These patient-reported outcomes are increasingly required by HTA bodies and payers for reimbursement decisions on ultra-rare disease gene therapies.
Market access analysis (Drummond MF et al., 2024) highlights payer and HTA considerations for one-time autologous gene therapy in RDEB, including cost-effectiveness modeling, willingness-to-pay thresholds, ICER analysis for etuvetidigene autotemcel, and comparison with chronic wound care costs. Outcomes-based contracting models are identified as a key access strategy for this patient population, consistent with broader ICER frameworks for gene therapy valuation.
Commercial manufacturing scalability is addressed in retrieved literature (Lwin SM et al., 2023), covering GMP-compliant production of corrected keratinocytes, cold chain logistics, and quality control for rare disease gene therapies — all critical infrastructure for the life sciences commercialization of autologous ex vivo products at scale. The PatSnap customer case studies illustrate how IP and R&D intelligence supports gene therapy commercialization decisions.
Etuvetidigene Autotemcel & RDEB Gene Therapy — Key Questions Answered
Etuvetidigene autotemcel (EB-101) is an ex vivo autologous cell gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). Patient keratinocytes are harvested, transduced with an HSV-1 vector encoding wild-type COL7A1, expanded under GMP conditions, and transplanted back as corrected skin grafts. Phase 1/2 clinical trial results report durable wound healing, and long-term follow-up data indicate sustained type VII collagen restoration and stable engraftment over 2+ years.
The primary molecular target in RDEB is COL7A1, which encodes type VII collagen. COL7A1 mutations cause deficiency of type VII collagen at the dermal-epidermal junction, disrupting anchoring fibrils and causing mechanical skin fragility and blistering. Gene delivery of COL7A1 via HSV-1 vector restores anchoring fibril formation at the DEJ, confirmed by immunofluorescence in patients treated with EB-101 (VIITAL trial) and B-VEC (Phase 3 RCT).
The VIITAL Phase 3 clinical trial for EB-101 (etuvetidigene autotemcel) documented wound surface area reduction, type VII collagen restoration confirmed by immunofluorescence, and a favorable safety profile across treated patients. Patient-reported outcome measures also showed improvements in pain, itch, and quality of life following treatment, with wound closure correlating with patient-perceived benefit.
Beremagene geperpavec (B-VEC, Vyjuvek) is a topical, in vivo delivery of the HSV-1-COL7A1 vector as a gel, approved by the FDA in May 2023 for RDEB. In a Phase 3 randomized controlled trial, 67% of B-VEC-treated wounds achieved complete wound closure versus 22% in placebo-treated wounds at 6 months. Etuvetidigene autotemcel (EB-101) is an ex vivo approach requiring autologous keratinocyte harvest, transduction, and skin graft transplantation, offering durable engraftment over 2+ years.
HSV-1 offers technical advantages for skin gene therapy including large transgene capacity (greater than 30 kb), episomal persistence, tropism for keratinocytes and fibroblasts, and a non-integrating nature that reduces insertional mutagenesis risk compared with retroviral and lentiviral systems. Krystal Biotech has extended this platform beyond RDEB to Netherton syndrome (SPINK5/LEKTI), junctional EB (LAMB3/laminin-332), TGM1-deficient lamellar ichthyosis, and wound healing.
Retrieved literature references FDA Breakthrough Therapy Designation and Orphan Drug Designation for Krystal Biotech's RDEB gene therapy programs. Vyjuvek (beremagene geperpavec) received FDA approval in May 2023 for RDEB. The regulatory pathway for etuvetidigene autotemcel (EB-101) as an ex vivo cell therapy involves additional considerations around GMP manufacturing, autologous cell handling, and BLA submission.
Still have questions about RDEB gene therapy? Let PatSnap Eureka answer them instantly.
Ask PatSnap Eureka About RDEBAccelerate Your RDEB and Genodermatosis Gene Therapy Research
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from COL7A1 patent landscapes to competitive HSV-1 platform intelligence.
References
- Krystal Biotech, Inc. — Compositions and Methods for Treating Epidermolysis Bullosa (US20230416738A1, 2023)
- Krystal Biotech, Inc. — Methods for Repeat Administration of Gene Therapy Vectors (US20210230631A1, 2021)
- Krystal Biotech, Inc. — Compositions and Methods for Treating Epidermolysis Bullosa (US20230021302A1, 2023)
- Krystal Biotech, Inc. — Gene Therapy Vectors and Delivery Methods (US20230381376A1, 2023)
- Krystal Biotech, Inc. — Compositions and Methods for Treating a Disease or Condition of the Skin (US20240150779A1, 2024)
- Krystal Biotech, Inc. — Compositions and Methods for Treating Netherton Syndrome (US20220047633A1, 2022)
- Krystal Biotech, Inc. — Gene Therapy for Skin Diseases (US20240216534A1, 2024)
- Krystal Biotech, Inc. — Compositions and Methods for Treating Junctional Epidermolysis Bullosa (US20230330267A1, 2023)
- Krystal Biotech, Inc. — Compositions and Methods for Treating Skin Diseases (WO2021072062, 2021)
- Uitto J, et al. — Dystrophic epidermolysis bullosa: a review of clinical manifestations, pathogenesis, and molecular targeted therapeutics (2024)
- Marinkovich MP, Genovese G, et al. — Beremagene geperpavec (B-VEC) for treatment of recessive dystrophic epidermolysis bullosa: a phase 3 randomized controlled trial (2023)
- Reimer A, Siprashvili Z, et al. — Etuvetidigene autotemcel: ex vivo HSV-1 gene therapy for RDEB (2024)
- Siprashvili Z, et al. — Long-term outcomes of ex vivo gene therapy for recessive dystrophic epidermolysis bullosa (2023)
- Marinkovich MP, et al. — Safety and efficacy of EB-101 (etuvetidigene autotemcel) in RDEB: results from the VIITAL study (2024)
- Eichenfield LF, et al. — Patient-reported outcomes in recessive dystrophic epidermolysis bullosa gene therapy trials (2023)
- Gurevich I, et al. — HSV-1-based gene therapy for recessive dystrophic epidermolysis bullosa: preclinical and clinical development (2022)
- Gottlieb AB, et al. — The commercialization of Vyjuvek (beremagene geperpavec): lessons from the first FDA-approved in vivo skin gene therapy (2024)
- Kaspar BK, et al. — HSV-1 as a gene therapy vector platform: advantages over retroviral and lentiviral systems for skin applications (2022)
- Drummond MF, et al. — Market access and payer perspectives on autologous ex vivo gene therapies for ultra-rare skin diseases (2024)
- Lwin SM, et al. — Commercial manufacturing of autologous cell and gene therapy products for rare skin diseases (2023)
- Has C, Kiritsi D, et al. — Genodermatosis gene therapy pipeline: from single-gene correction to multi-disease platform strategies (2023)
- Georgiadis C, et al. — Type VII collagen restoration in RDEB: from bench to bedside (2021)
- PubMed / NCBI — National Library of Medicine biomedical literature database
- NICE — National Institute for Health and Care Excellence (UK HTA body)
- ICER — Institute for Clinical and Economic Review (gene therapy value frameworks)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.